Lupin said it expects to make Aplevant available in India this month itself.
The two companies already have a partnership dating back to 2011.
With this, said Lupin, the partnership has been expanded to include the promotion and distribution of Lilly’s diabetes portfolio in India.
Lupin claims to be the fastest growing company in the Indian diabetes market and to be ranked as the third largest company in the Anti-diabetes market in India on a MAT basis as of August 2018
Rajeev Sibal, President – India Region Formulations, Lupin said his company hoped to ‘continue building its product pipeline through strategic tie-ups’.
Luca Visini, Managing Director, Lilly India said his company was the first to commercially release insulin in 1923, the first to offer biosynthetic ‘human’ insulin with recombinant DNA technology, the first to come up with rapid insulin analog and so on.
Financial details of the deal were not revealed.